Home World News Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses... World News Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma By Ogkologos - October 5, 2026 74 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the first-in-human phase I study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Zanidatamab June 5, 2025 The Future Front Line: Pre-Med During COVID-19 September 8, 2020 Revumenib Shows Promise in Treating Advanced Acute Myeloid Leukemia April 18, 2023 Majority of Patients With Cancer Are Willing To Be Vaccinated Against... February 2, 2021 Load more HOT NEWS Picking out the sound of tumours Luspatercept Improves the Rate of RBC Transfusion Independence Compared with Epoetin... World Cancer Day 2023: where does the UK stand? What Are Biosimilars in Cancer Treatment?
